Effect of oral administration of essential oil from peel (EOP) and seed (EOS) from <i>C</i>. <i>adamantium</i> fruits in formalin-induced paw licking.

<p>Essential oil of EOS and EOP at doses of 100 and 300 mg/kg shows antinociceptive effects in phase I and II test. Results represent mean ± S.E.M. (n = 6). * <i>P</i> < 0.05, when compared to control group. Each bar represents the mean ± SEM of 5 animals. * <i>p</i> <0.001 when compared to control group. Differences among groups were analyzed by analysis of variance (one-way ANOVA) followed by the Newman-Keuls test.</p

Effect of oral administration of essential oil from peel (EOP) and seed (EOS) in inhibition of leukocyte migration at both doses tested in pleurisy test.

<p>Mice were treated one hour before an intrapleural injection of carrageenan, with EOS and EOP (100 or 300 mg/kg), dexamethasone (dexa, 1 mg/kg, s.c.), or saline solution (Vehicle). Naive group, also treated with saline p.o., received an intrapleural injection of sterile saline. The bars express the mean ± SEM of 5 animals. * p<0.001 when compared to control group. Differences between groups were analyzed by analysis of variance (one-way ANOVA) followed by the Newman-Keuls test.</p

Relative weight organs of mice treated for 14 days with the oil extracted from the peel and seed of <i>Campomanesia adamantium</i> in the acute toxicity study.

<p>Relative weight organs of mice treated for 14 days with the oil extracted from the peel and seed of <i>Campomanesia adamantium</i> in the acute toxicity study.</p

Evaluation of weight, water consumption and feed after treatment for 14 days with the oil extracted from the peel and seed of <i>Campomanesia adamantium</i> in the acute toxicity study with mice.

<p>Evaluation of weight, water consumption and feed after treatment for 14 days with the oil extracted from the peel and seed of <i>Campomanesia adamantium</i> in the acute toxicity study with mice.</p

Composition of the volatile compounds indentified in the essential oils of the peel and seed of <i>Campomanesia adamantium</i> fruits.

<p>Composition of the volatile compounds indentified in the essential oils of the peel and seed of <i>Campomanesia adamantium</i> fruits.</p

Effect of oral administration of essential oil from peel (EOP) and seed (EOS) from <i>Campomanesia adamantiun</i> in carrageenan-induced paw oedema in mice.

<p>Animals received EOP and EOS (100 or 300 mg/kg, p.o.) or control (vehicle) or dexamethasone (DEXA, 1 mg/kg, s.c.) and after 1 h an intraplantar injection of carrageenan (300 μg/paw) for evaluation of paw oedema for (A) 1, (B) 2, (C) 3, and (D) 4 h after carrageenan injection. Each bar represents the mean ± SEM of 5 animals. * p <0.001 when compared with the control group. Differences between groups were analyzed by analysis of variance (one-way ANOVA) followed by the Newman-Keuls test.</p

Effect of the <i>A</i>. <i>phalerata</i> oil on the leukocyte migration induced by carrageenan in the pleurisy model in rats.

<p>Values expressed in mean ± standard error of the mean. n = 5. * P <0.05 (ANOVA / Tukey) compared with the negative control (-).</p

Anti-inflammatory, antiproliferative and cytoprotective potential of the <i>Attalea phalerata</i> Mart. ex Spreng. pulp oil - Fig 5

<p>Effect of the <i>A</i>. <i>phalerata</i> oil on the paw edema after 0.5h (A), 1h (B), 2h (C) and 4h (D) of the intraplantar carrageenan injection. Values expressed in mean ± standard error of the mean. n = 5. * P <0.05 (ANOVA / Tukey) compared with the negative control (-).</p

Effect of the <i>A</i>. <i>phalerata</i> oil in COX1 and COX2 inhibition.

<p>Values expressed in mean ± standard error of the mean. n = 4. * P <0.05 (ANOVA / Tukey) compared with the negative control (-).</p

<i>In vitro</i> protective effect of <i>A</i>. <i>phalerata</i> oil under murine fibroblast cells (NIH / 3T3).

<p>The control represents untreated cells. A1, A2, A3 and A4 are evaluated treatment with doxorrubicina 0.025, 0.25, 2.5 and 25 μg mL^-1, respectively. B1, B2, B3 and B4 are evaluated treatment with APOP 250, 500, 1000 and 2000 μg mL^-1, respectively. C1-C4 are evaluated treatment combinations: (C1) used doxorrubicina on 0.025 μg mL^-1 and <i>A</i>. <i>phalerata</i> oil on 250 μg mL^-1; (C2) doxorrubicina on 0.25 μg mL^-1 and <i>A</i>. <i>phalerata</i> oil on 500 μg mL^-1; (C3) doxorrubicina on 2.5 μg mL^-1 and <i>A</i>. <i>phalerata</i> oil on 1000 μg mL^-1 (C4) doxorrubicina on 25 μg mL^-1 and <i>A</i>. <i>phalerata</i> oil on 2000 μg mL^-1. Values expressed in mean ± standard error of the mean. n = 3. * P <0.05 (ANOVA / Tukey) compared with the untreated cells.</p